GlassScriptPhysician profile
Georg J Couturier
NPI 1710952486
$23,131.09
in general payments reported to CMS, 2019-2025
43 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,763 · 2020: $2,696 · 2021: $597 · 2022: $1,675 · 2023: $2,044 · 2024: $1,353 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,421 · Food and Beverage: $4,959 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,420.70 |
| Food and Beverage | $4,958.90 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $8,674.34 | 2019-2025 | Biomonitor, Renamic Neo, Amvia Edge |
| Abbott Laboratories | $1,880.51 | 2019-2025 | Aveir, Mitraclip, Jot Dx |
| Boston Scientific Corporation | $1,858.85 | 2019-2025 | General - Tachy, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Medtronic Vascular, INC. | $1,840.56 | 2019-2020 | |
| Medtronic, INC. | $1,133.24 | 2021-2025 | Cobalt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan, Symplicity G3 |
| Janssen Pharmaceuticals, INC | $868.69 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $831.98 | 2019-2025 | Jardiance |
| Amgen INC. | $607.23 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $586.37 | 2019-2022 | |
| Pfizer INC. | $549.78 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $520.32 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $496.48 | 2019-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $478.66 | 2022-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $412.89 | 2019-2025 | Farxiga, Brilinta, Lokelma |
| Sanofi-Aventis U.S. LLC | $350.77 | 2019-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georg Couturier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.